FibroFoundation Profile Banner
Fibrolamellar Cancer Profile
Fibrolamellar Cancer

@FibroFoundation

Followers
680
Following
787
Media
66
Statuses
1K

Fibrolamellar Cancer Foundation's official Twitter page. Focused on finding effective treatments for #fibrolamellar carcinoma (a rare form of liver cancer).

All over!
Joined May 2009
Don't wanna be here? Send us removal request.
@FibroFoundation
Fibrolamellar Cancer
3 months
FCF is pleased to announce that it has awarded an research grant to Dr. Hugo Jimenez of Wayne State University to investigate the effectiveness of using low energy electromagnetic fields to treat fibrolamellar carcinoma (FLC).
Tweet media one
0
1
1
@FibroFoundation
Fibrolamellar Cancer
3 months
FCF is pleased to announce that it is funding a 16-patient extension of a clinical trial at Johns Hopkins. The trial is testing the ability of a FLC-specific vaccine to produce an immune response against the disease.
Tweet media one
0
1
3
@FibroFoundation
Fibrolamellar Cancer
10 months
Marina Baretti, MD of Johns Hopkins University describes recently approved protocol changes to a clinical trial for FLC patients that will allow enrolled patients to self-administer the glutamine antagonist drug (DRP-104) at home.
fibrofoundation.org
Marina Baretti, MD of Johns Hopkins University recently provided an update on a clinical trial for fibrolamellar patients that intends to leverage the “glutam
0
1
4
@FibroFoundation
Fibrolamellar Cancer
10 months
FCF is pleased to announce that it has awarded a grant to Dr. Juliane Walz of the University Hospital Tübingen for a clinical trial testing a therapeutic peptide vaccine as an adjuvant therapy.
fibrofoundation.org
We are pleased to announce that FCF has awarded Dr. Juliane Walz of the University Hospital Tübingen a grant to develop and launch a new clinical trial for FL
0
1
4
@FibroFoundation
Fibrolamellar Cancer
1 year
A FEW MORE SPOTS ARE AVAILABLE. Registration is now OPEN for the 2024 Patient & Family Gathering in Stowe, Vermont.Sept 13 - Sept 15, 2024.SPACE IS LIMITED.Click on the link below to register.
Tweet card summary image
fibrofoundation.org
Group photo at September 2023 Gathering The Fibrolamellar Cancer Foundation will be hosting the 2024 Patient & Family Gathering at the Lake Mansfield Tro
0
0
1
@FibroFoundation
Fibrolamellar Cancer
1 year
FCF is pleased to announce that it has awarded a grant to Sean Ronnekleiv-Kelly, MD of the University of Wisconsin-Madison School of Medicine to determine if targeting CDK7 could be a useful treatment approach for FLC.
0
0
5
@FibroFoundation
Fibrolamellar Cancer
1 year
FCF is please to announce that in-person and virtual registration is now open for FCF's second Fibrolamellar Patient & Research Summit to be held on June 9-10, 2024 in Greenwich, Connecticut.
0
0
2
@FibroFoundation
Fibrolamellar Cancer
1 year
Mark Yarchoan, MD and Marina Baretti, MD of Johns Hopkins University discuss the launch of a clinical trial of the glutamine antagonist DRP-104 for fibrolamellar patients.
Tweet media one
0
0
2
@FibroFoundation
Fibrolamellar Cancer
2 years
FCF is proud to be the recipient of the Ryan Couling Memorial Hockey Tournament Fundraiser. RCMT donated $8,062.50 to FCF. We are very grateful to the Couling Family!.To learn more about Ryan, and RCMT, please visit their website:. .
0
2
4
@FibroFoundation
Fibrolamellar Cancer
2 years
You can play a crucial role in funding groundbreaking research & clinical trials to improve treatment options for FLC patients. Your donations “fund the fight” & move us closer to a future free from FLC. 100% of donations to FCF directly fund research.
fibrofoundation.org
Each year, the Tuesday after Thanksgiving celebrates giving as a way to transform the world. Giving Tuesday was created in 2012 as a day that encourages people
0
0
0
@FibroFoundation
Fibrolamellar Cancer
2 years
FCF is please to announce that it has funded a new multi-institutional study directed by Roshni Dasgupta, MD of the Cincinnati Children’s Hospital (CCHMC) to better understand the incidence and accuracy of diagnosis of FLC.
Tweet media one
0
1
5
@FibroFoundation
Fibrolamellar Cancer
2 years
This week, a clinical trial of a peptide vaccine (FusionVAC22) in combination with an immune checkpoint inhibitor (atezolizumab) treated its first patient in Tübingen, Germany.
Tweet media one
0
2
7
@FibroFoundation
Fibrolamellar Cancer
2 years
FCF is please to announce that it has awarded a grant for additional studies to be conducted by John Scott, PhD of the University of Washington in Seattle.
Tweet media one
0
0
3
@FibroFoundation
Fibrolamellar Cancer
2 years
Thank you to Stone Point Capital, as well as the sponsors and participants in the 2023 Stone Point Capital Charity Golf Tournament. This years event, held on October 2nd, raised a record amount of funding for the Foundation.
Tweet media one
0
0
3
@FibroFoundation
Fibrolamellar Cancer
2 years
October is Liver Cancer Awareness Month, a chance to raise awareness and funds to improve the detection and treatment of these diseases, plus show support for those who have heard the terrifying words - "you have liver cancer.".
Tweet media one
1
3
3
@FibroFoundation
Fibrolamellar Cancer
2 years
September 30 is Rare Cancer Day! Spearheaded by the NORD's Rare Cancer Coalition, Rare Cancer Day is observed on September 30 each year to highlight the challenges facing rare cancer patients and the need for greater research funding.
Tweet media one
0
0
4
@FibroFoundation
Fibrolamellar Cancer
2 years
While childhood cancer is rare, it is the leading disease-related cause of death in children and adolescents. In recognition of this issue, September is internationally recognized as "Childhood Cancer Awareness Month".
Tweet media one
0
1
1
@FibroFoundation
Fibrolamellar Cancer
2 years
FCF is please to announce that it has established a new partnership with the Center for Patient Derived Models (CPDM) at the Dana Farber Cancer Institute in Boston. #DanaFarber.
Tweet media one
0
1
4
@FibroFoundation
Fibrolamellar Cancer
2 years
FCF awards a grant to support a clinical trial of a glutamine antagonist in combination with a checkpoint inhibitor at Johns Hopkins University.
Tweet media one
0
1
2
@FibroFoundation
Fibrolamellar Cancer
2 years
FCF has entered into a partnership agreement with a private clinical-stage biotech to support an upcoming clinical trial. Under the agreement, Dracen Pharmaceuticals will provide DRP-104 (sirpiglenastat), a glutamine antagonist pro-drug, for the effort.
Tweet media one
0
1
2